Trial Profile
A Longitudinal Study Comparing SF2/ASF Modulation in Multiple Sclerosis (MS) Patients Treated with Natalizumab and Fingolimod and Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Fingolimod
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics
- 20 Feb 2018 New trial record